Generic Dojolvi Availability
Last updated on Aug 7, 2024.
Dojolvi is a brand name of triheptanoin, approved by the FDA in the following formulation(s):
DOJOLVI (triheptanoin - liquid;oral)
-
Manufacturer: ULTRAGENYX PHARM INC
Approval date: June 30, 2020
Strength(s): 100% w/w [RLD]
Has a generic version of Dojolvi been approved?
No. There is currently no therapeutically equivalent version of Dojolvi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dojolvi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Glycogen or polysaccharide storage disease treatment method
Patent 8,697,748
Issued: April 15, 2014
Inventor(s): Roe Charles R.
Assignee(s): Baylor Research InstituteA method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.
Patent expiration dates:
- April 28, 2029✓
- April 28, 2029
-
Glycogen or polysaccharide storage disease treatment method
Patent 9,186,344
Issued: November 17, 2015
Inventor(s): Roe Charles R.
Assignee(s): BAYLOR RESEARCH INSTITUTEA method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.
Patent expiration dates:
- July 1, 2025✓
- July 1, 2025
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- June 30, 2025 - NEW CHEMICAL ENTITY
- June 30, 2027 - INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS FOR THE TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH MOLECULARLY CONFIRMED LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD)
More about Dojolvi (triheptanoin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: oral nutritional supplements
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.